{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:33:32Z","timestamp":1790303612706,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"the Swedish Cancer Society","award":["130260"],"award-info":[{"award-number":["130260"]}]},{"name":"the Swedish Cancer Society","award":["140616"],"award-info":[{"award-number":["140616"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13048-016-0239-6","type":"journal-article","created":{"date-parts":[[2016,5,14]],"date-time":"2016-05-14T12:37:35Z","timestamp":1463229455000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer"],"prefix":"10.1186","volume":"9","author":[{"given":"\u00c5sa","family":"Fransson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Glaessgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Alfredsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klas G.","family":"Wiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Bajalica-Lagercrantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Mohell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,14]]},"reference":[{"key":"239_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","volume":"124","author":"J Prat","year":"2014","unstructured":"Prat J, Oncology FCoG. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124:1\u20135.","journal-title":"Int J Gynaecol Obstet"},{"key":"239_CR2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/PAT.0b013e32835f2264","volume":"45","author":"D Lim","year":"2013","unstructured":"Lim D, Oliva E. Precursors and pathogenesis of ovarian carcinoma. Pathology. 2013;45:229\u201342.","journal-title":"Pathology"},{"key":"239_CR3","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/PAS.0b013e3181ef7b16","volume":"34","author":"CG Przybycin","year":"2010","unstructured":"Przybycin CG, Kurman RJ, Ronnett BM, Shih Ie M, Vang R. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol. 2010;34:1407\u201316.","journal-title":"Am J Surg Pathol"},{"key":"239_CR4","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nrc4019","volume":"15","author":"DD Bowtell","year":"2015","unstructured":"Bowtell DD, Bohm S, Ahmed AA, Aspuria PJ, Bast Jr RC, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;15:668\u201379.","journal-title":"Nat Rev Cancer"},{"key":"239_CR5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/path.2696","volume":"221","author":"AA Ahmed","year":"2010","unstructured":"Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio A, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010;221:49\u201356.","journal-title":"J Pathol"},{"key":"239_CR6","unstructured":"Soussi T. The p53 Web Site. http:\/\/p53.fr . Updated 01\/2013."},{"key":"239_CR7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00439-014-1470-0","volume":"134","author":"DL Masica","year":"2015","unstructured":"Masica DL, Li S, Douville C, Manola J, Ferris RL, Burtness B, Forastiere AA, Koch WM, Chung CH, Karchin R. Predicting survival in head and neck squamous cell carcinoma from TP53 mutation. Hum Genet. 2015;134:497\u2013507.","journal-title":"Hum Genet"},{"key":"239_CR8","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.cell.2009.04.037","volume":"137","author":"KH Vousden","year":"2009","unstructured":"Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell. 2009;137:413\u201331.","journal-title":"Cell"},{"key":"239_CR9","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ccr.2009.03.003","volume":"15","author":"JM Lambert","year":"2009","unstructured":"Lambert JM, Gorzov P, Veprintsev DB, Soderqvist M, Segerback D, Bergman J, Fersht AR, Hainaut P, Wiman KG, Bykov VJ. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell. 2009;15:376\u201388.","journal-title":"Cancer Cell"},{"key":"239_CR10","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/onc.2009.425","volume":"29","author":"JM Lambert","year":"2010","unstructured":"Lambert JM, Moshfegh A, Hainaut P, Wiman KG, Bykov VJ. Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis. Oncogene. 2010;29:1329\u201338.","journal-title":"Oncogene"},{"key":"239_CR11","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1200\/JCO.2011.40.7783","volume":"30","author":"S Lehmann","year":"2012","unstructured":"Lehmann S, Bykov VJ, Ali D, Andren O, Cherif H, Tidefelt U, Uggla B, Yachnin J, Juliusson G, Moshfegh A, et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol. 2012;30:3633\u20139.","journal-title":"J Clin Oncol"},{"key":"239_CR12","doi-asserted-by":"crossref","first-page":"e1794","DOI":"10.1038\/cddis.2015.143","volume":"6","author":"N Mohell","year":"2015","unstructured":"Mohell N, Alfredsson J, Fransson A, Uustalu M, Bystrom S, Gullbo J, Hallberg A, Bykov VJ, Bjorklund U, Wiman KG. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. Cell Death Dis. 2015;6:e1794.","journal-title":"Cell Death Dis"},{"key":"239_CR13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1757-2215-6-7","volume":"6","author":"N Kobayashi","year":"2013","unstructured":"Kobayashi N, Abedini M, Sakuragi N, Tsang BK. PRIMA-1 increases cisplatin sensitivity in chemoresistant ovarian cancer cells with p53 mutation: a requirement for Akt down-regulation. J Ovarian Res. 2013;6:7.","journal-title":"J Ovarian Res"},{"key":"239_CR14","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/ncomms3126","volume":"4","author":"S Domcke","year":"2013","unstructured":"Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun. 2013;4:2126.","journal-title":"Nat Commun"},{"key":"239_CR15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ygyno.2015.08.017","volume":"139","author":"KM Elias","year":"2015","unstructured":"Elias KM, Emori MM, Papp E, MacDuffie E, Konecny GE, Velculescu VE, Drapkin R. Beyond genomics: Critical evaluation of cell line utility for ovarian cancer research. Gynecol Oncol. 2015;139:97\u2013103.","journal-title":"Gynecol Oncol"},{"key":"239_CR16","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","volume":"28","author":"A Malpica","year":"2004","unstructured":"Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004;28:496\u2013504.","journal-title":"Am J Surg Pathol"},{"key":"239_CR17","unstructured":"Regionalt cancercentrum v\u00e4st: \u00c4ggstockscancer Nationellt v\u00e5rdprogram. 2005. http:\/\/www.cancercentrum.se\/globalassets\/cancerdiagnoser\/gynekologi\/aggstockscancer\/natvp_ovarialcancer_v2.0_3jun15_final.pdf ."},{"key":"239_CR18","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/nprot.2008.114","volume":"3","author":"E Lindhagen","year":"2008","unstructured":"Lindhagen E, Nygren P, Larsson R. The fluorometric microculture cytotoxicity assay. Nat Protoc. 2008;3:1364\u20139.","journal-title":"Nat Protoc"},{"key":"239_CR19","first-page":"895","volume":"59","author":"F Valeriote","year":"1975","unstructured":"Valeriote F, Lin H. Synergistic interaction of anticancer agents: a cellular perspective. Cancer Chemother Rep. 1975;59:895\u2013900.","journal-title":"Cancer Chemother Rep"},{"key":"239_CR20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hon.2900090203","volume":"9","author":"E Lepri","year":"1991","unstructured":"Lepri E, Barzi A, Menconi E, Portuesi MG, Liberati M. In vitro synergistic activity of PDN-IFN alpha and NM\u2009+\u2009IFN alpha combinations on fresh bone-marrow samples from multiple myeloma patients. Hematol Oncol. 1991;9:79\u201386.","journal-title":"Hematol Oncol"},{"key":"239_CR21","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s002280050505","volume":"54","author":"E Jonsson","year":"1998","unstructured":"Jonsson E, Fridborg H, Nygren P, Larsson R. Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients. Eur J Clin Pharmacol. 1998;54:509\u201314.","journal-title":"Eur J Clin Pharmacol"},{"key":"239_CR22","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/0888-7543(89)90129-8","volume":"5","author":"M Orita","year":"1989","unstructured":"Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics. 1989;5:874\u20139.","journal-title":"Genomics"},{"key":"239_CR23","doi-asserted-by":"crossref","unstructured":"Lheureux S, Karakasis K, Kohn EC, Oza AM. Ovarian cancer treatment: The end of empiricism? Cancer. 2015.","DOI":"10.1002\/cncr.29481"},{"key":"239_CR24","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/jjco\/hyv014","volume":"45","author":"K Matsumoto","year":"2015","unstructured":"Matsumoto K, Onda T, Yaegashi N. Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives. Jpn J Clin Oncol. 2015;45:408\u201310.","journal-title":"Jpn J Clin Oncol"},{"key":"239_CR25","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","volume":"7","author":"L Kelland","year":"2007","unstructured":"Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7:573\u201384.","journal-title":"Nat Rev Cancer"},{"key":"239_CR26","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","volume":"22","author":"ZH Siddik","year":"2003","unstructured":"Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22:7265\u201379.","journal-title":"Oncogene"},{"key":"239_CR27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","volume":"33","author":"CA Rabik","year":"2007","unstructured":"Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007;33:9\u201323.","journal-title":"Cancer Treat Rev"},{"key":"239_CR28","doi-asserted-by":"crossref","first-page":"972913","DOI":"10.1155\/2013\/972913","volume":"2013","author":"N Traverso","year":"2013","unstructured":"Traverso N, Ricciarelli R, Nitti M, Marengo B, Furfaro AL, Pronzato MA, Marinari UM, Domenicotti C. Role of glutathione in cancer progression and chemoresistance. Oxid Med Cell Longev. 2013;2013:972913.","journal-title":"Oxid Med Cell Longev"},{"key":"239_CR29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/bjc.1991.279","volume":"64","author":"P Mistry","year":"1991","unstructured":"Mistry P, Kelland LR, Abel G, Sidhar S, Harrap KR. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer. 1991;64:215\u201320.","journal-title":"Br J Cancer"},{"key":"239_CR30","doi-asserted-by":"crossref","first-page":"6571","DOI":"10.1038\/onc.2008.249","volume":"27","author":"J Shen","year":"2008","unstructured":"Shen J, Vakifahmetoglu H, Stridh H, Zhivotovsky B, Wiman KG. PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2. Oncogene. 2008;27:6571\u201380.","journal-title":"Oncogene"},{"key":"239_CR31","doi-asserted-by":"crossref","first-page":"e881","DOI":"10.1038\/cddis.2013.417","volume":"4","author":"X Peng","year":"2013","unstructured":"Peng X, Zhang MQ, Conserva F, Hosny G, Selivanova G, Bykov VJ, Arner ES, Wiman KG. APR-246\/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 2013;4:e881.","journal-title":"Cell Death Dis"},{"key":"239_CR32","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","volume":"177","author":"E Lengyel","year":"2010","unstructured":"Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010;177:1053\u201364.","journal-title":"Am J Pathol"},{"key":"239_CR33","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1040-8428(00)00086-X","volume":"36","author":"B Desoize","year":"2000","unstructured":"Desoize B, Jardillier J. Multicellular resistance: a paradigm for clinical resistance? Crit Rev Oncol Hematol. 2000;36:193\u2013207.","journal-title":"Crit Rev Oncol Hematol"},{"key":"239_CR34","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1002\/jcb.23199","volume":"112","author":"A Latifi","year":"2011","unstructured":"Latifi A, Abubaker K, Castrechini N, Ward AC, Liongue C, Dobill F, Kumar J, Thompson EW, Quinn MA, Findlay JK, Ahmed N. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J Cell Biochem. 2011;112:2850\u201364.","journal-title":"J Cell Biochem"},{"key":"239_CR35","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.chembiol.2010.04.012","volume":"17","author":"Y Pommier","year":"2010","unstructured":"Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010;17:421\u201333.","journal-title":"Chem Biol"},{"issue":"Suppl 1","key":"239_CR36","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1517\/14728222.2011.640322","volume":"16","author":"S Knappskog","year":"2012","unstructured":"Knappskog S, Lonning PE. P53 and its molecular basis to chemoresistance in breast cancer. Expert Opin Ther Targets. 2012;16 Suppl 1:S23\u201330.","journal-title":"Expert Opin Ther Targets"},{"key":"239_CR37","doi-asserted-by":"crossref","first-page":"18641","DOI":"10.18632\/oncotarget.4080","volume":"6","author":"BL Seagle","year":"2015","unstructured":"Seagle BL, Eng KH, Dandapani M, Yeh JY, Odunsi K, Shahabi S. Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers. Oncotarget. 2015;6:18641\u201352.","journal-title":"Oncotarget"},{"key":"239_CR38","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3892\/ijo.2014.2747","volume":"46","author":"P Brachova","year":"2015","unstructured":"Brachova P, Mueting SR, Carlson MJ, Goodheart MJ, Button AM, Mott SL, Dai D, Thiel KW, Devor EJ, Leslie KK. TP53 oncomorphic mutations predict resistance to platinum and taxanebased standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma. Int J Oncol. 2015;46:607\u201318.","journal-title":"Int J Oncol"},{"key":"239_CR39","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1038\/sj.onc.1208419","volume":"24","author":"VJ Bykov","year":"2005","unstructured":"Bykov VJ, Zache N, Stridh H, Westman J, Bergman J, Selivanova G, Wiman KG. PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene. 2005;24:3484\u201391.","journal-title":"Oncogene"},{"key":"239_CR40","doi-asserted-by":"crossref","first-page":"19257","DOI":"10.3390\/ijms140919257","volume":"14","author":"P Brachova","year":"2013","unstructured":"Brachova P, Thiel KW, Leslie KK. The consequence of oncomorphic TP53 mutations in ovarian cancer. Int J Mol Sci. 2013;14:19257\u201375.","journal-title":"Int J Mol Sci"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-016-0239-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T13:43:08Z","timestamp":1567863788000},"score":1,"resource":{"primary":{"URL":"http:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-016-0239-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,14]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["239"],"URL":"https:\/\/doi.org\/10.1186\/s13048-016-0239-6","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,14]]},"article-number":"27"}}